Concepedia

Ray Lin

RL

16

Publications

1.5K

Citations

14

H-Index

2000

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Stanford University

Pfizer (United States)

Dana-Farber Cancer Institute

Yale Cancer Center

Ray Lin is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and radiation oncology.

Top concepts

Publications per year

2000–2021

16

Publications

16

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Debashis Sarker, Joo Ern Ang, Richard D. Baird et al. · Clinical Cancer Research · 2014 · 341 citations · Full text

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Kyung Hae Jung, Patricia LoRusso, Howard A. Burris et al. · Clinical Cancer Research · 2019 · 281 citations · Full text

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko et al. · Journal of Clinical Oncology · 2018 · 220 citations

, , +16

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Dejan Juric, Ian E. Krop, Ramesh K. Ramanathan et al. · Cancer Discovery · 2017 · 159 citations · Full text

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

Asha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek et al. · Journal for ImmunoTherapy of Cancer · 2018 · 150 citations · Full text

Rows per page

1–5 of 16